Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

safety and efficacy of CDP-1050, the availability of CDP-1050 worldwide to treat ill heart failure patients, ATPace's expected entry into a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, and CDP-1050's expected commencement of a Phase 2 clinical trial for the treatment of heart failure. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 may not be successful, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Cordex on the date hereof. Cordex undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... German . , ... in a semiconductor layer. Quantum dots are small structures that ... a short laser pulse is fired at the photonic crystal, ... a change in the electromagnetic field around it. This change ... by the dot. As soon as the refractive index recovers ...
(Date:9/30/2014)... available in German . ... Mnchen (TUM) have demonstrated a new kind of building ... future computer chips could be based on three-dimensional arrangements ... enabling technology of the semiconductor industry CMOS fabrication ... researchers and collaborators at the University of Notre Dame ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... Review - 2014 Summary Global Markets ... Review - 2014, provides an overview of the ... focus. This report provides comprehensive information on ... Biotechnology, LLC,s, complete with comparative analysis at various ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released the DSES-1000 ... tool for measuring displacement in rubber and other ... movement distance, the DSES-1000 can measure elongations up ... 10 mm. In addition, it achieves +/- 0.2 ... within +/- 100 µm below 50-mm stroke. , ...
Breaking Biology Technology:Ultrafast remote switching of light emission 2A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2
... (Nasdaq: DNDN ) today announced significant ... of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy ... metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC). ... and Drug Administration (FDA) approved the Los Angeles ...
... JERICHO, N.Y., June 30, 2011 ( HCCS ) ... online healthcare compliance and competency training, today announced the ... Management System , SimPL - The Simple ... management features to the existing online training and eLearning ...
... The National Parkinson Foundation (NPF) has awarded more ... Through NPF,s individual investigators awards program, NPF is supporting work ... an advanced biomarker study, 2) a clinical trial to treat ... a treatment for sleep apnea in PD. "Each ...
Cached Biology Technology:Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 2Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 3Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 4HCCS Releases Classroom Management Features for Low Cost Learning Management System 2National Parkinson Foundation Awards More Than $1 Million for Research 2National Parkinson Foundation Awards More Than $1 Million for Research 3
(Date:9/30/2014)... MILFORD, Mass. , Sept. 30, 2014 ... process control solutions for the biotech and ... of its new RECONN Bioprocess Manager, an ... reporting solution geared towards bioprocess development laboratories. ... facilities have disparate bioreactor and analyzer systems. ...
(Date:9/30/2014)... HONG KONG , Sept. 30, 2014 Winners of ... The Economist Events, Innovation Summit scheduled to take place at the ... At the summit, the award winners will share their experiences and ... people who have made a proven innovation over the past decade, ... the night before the summit. It will be the ...
(Date:9/29/2014)... Plants have a symbiotic relationship with certain bacteria. ... and defend against invaders an important step ... Now, scientist have discovered that plants may package ... that sprouting plants are colonized from the beginning. ... presented their findings today at the 5th ASM ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Plants prepackage beneficial microbes in their seeds 2
... to put a price tag on the natural world? A ... rise of a new concept ecosystem services to ... Nature. Academic Dr Marion Potschin, of the University,s Centre ... who have been investigating the ethical considerations of this new ...
... . , Biopesticides containing beneficial fungi are ... Department of Agriculture (USDA) scientists have shown a liquid ... "liquid culture fermentation," offers several benefits, including lower material ... fungi, including Isaria or Metarhizium , ...
... CALGARY Researchers in Calgary have launched the first gene therapy ... enzyme deficiency that can shorten the lifespan of people who have ... first remove a quantity of stem cells from a Fabry patient,s ... inserted into the stem cells using a specially engineered virus. During ...
Cached Biology News:Valuing nature is not enough 2New, cost-cutting approach to formulating pest-killing fungi 2Canada launches first gene therapy trial for Fabry disease 2Canada launches first gene therapy trial for Fabry disease 3
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
... 435 is an affordable, compact benchtop ... slides, providing a broad array of ... acquires high-resolution images with high-performance laser ... excitation and emission filter changers, and ...
... Contents include: Microarray hybridization chamber ... chamber top, clamp, thumbscrew) Microarray chamber user ... and are intended to be cleaned and ... with Agilents Catalog Oligo Microarray kits and ...
Biology Products: